Canada Issues Patent for Ovarian Cancer Vaccine

Canadian Intellectual Property Office grants Anixa Biosciences a patent covering key aspects of its ovarian cancer vaccine technology.

Updated on Nov. 21, 2026 in Cancer

Bold vector editorial illustration of a single rounded teal immune cell ringed by mustard protein shapes on a cream field, evoking a targeted cancer-vaccine approach.
Canada's Intellectual Property Office granted Anixa Biosciences Patent No. 3,005,025 for its ovarian cancer vaccine technology, complementing a US patent issued in July 2025. AI Illustration. Upload story photo >

The Canadian Intellectual Property Office has issued Patent Number 3,005,025 to Anixa Biosciences for its ovarian cancer vaccine technology. The patent complements a US patent Anixa announced in July 2025 covering the same technology.

Why it matters

The patent extends legal protection for an ovarian cancer vaccine approach that aims to train the immune system to target cancer-associated cells. Anixa's stated long-term goal is to prevent ovarian cancer before it develops.

The Canadian patent is one of two issued for the technology, the other being US Patent Number 12,357,593 announced in July 2025. Whether the vaccine has advanced to human ovarian cancer trials is not addressed in the source.

The players

Anixa Biosciences

A biotechnology company that develops immunotherapies, including ovarian and breast cancer vaccines and the lira-cel cell therapy developed with Moffitt Cancer Center.

Cleveland Clinic

A nonprofit academic medical center in Ohio that licensed the ovarian cancer vaccine patent exclusively to Anixa and collaborated on its research.

The details

The patent, titled "Ovarian Cancer Vaccines," is exclusively licensed from Cleveland Clinic and covers methods of immunizing against the extracellular domain of anti-Müllerian hormone receptor II. Its co-inventors are Dr. Justin Johnson, the late Dr. Vincent Tuohy, and Dr. Suparna Mazumder, and the vaccine exploits differences in protein expression between normal tissues and cancer cells.

Timeline

  1. July 2025: Anixa announced issuance of US Patent Number 12,357,593 covering its ovarian cancer vaccine technology.

  2. November 21, 2026: The Canadian patent announcement was published.

Clinical Context

The ovarian cancer patent extends the same vaccine platform behind Anixa's breast cancer vaccine, which completed a Phase 1 trial funded by a US Department of Defense grant with all primary endpoints met. The patent does not itself indicate that the ovarian vaccine has reached the same stage.

The patent does not change how ovarian cancer is treated today, since the source does not report that the vaccine is available to patients. Readers seeking current options should consult their own clinicians about screening and treatment.

The takeaway

Patents secure legal rights to a technology but do not by themselves show that a treatment works or is available. Ovarian cancer vaccine development should be followed through clinical trial results rather than patent issuance alone.

Further reading

Explore more coverage in the Cancer section.

Source note: This article includes information reported by Pharmabiz.